kabutan

Meiji Holdings Co., Ltd.(2269) Summary

2269
TSE Prime
Meiji Holdings Co., Ltd.
3,284.0
JPY
-17.0
(-0.51%)
Dec 12, 3:30 pm JST
21.07
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
3,279.1
Dec 12, 11:25 pm JST
Summary Chart Historical News Financial Result
PER
16.4
PBR
1.19
Yield
3.20%
Margin Trading Ratio
5.26
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
3,300.0 JPY 21.22 USD
Previous Close Dec 11
3,301.0 JPY 21.14 USD
High Dec 12, 10:16 am
3,318.0 JPY 21.32 USD
Low Dec 12, 1:13 pm
3,284.0 JPY 21.07 USD
Volume
1,604,200
Trading Value
5.29B JPY 0.03B USD
VWAP
3294.9 JPY 21.15 USD
Minimum Trading Value
328,400 JPY 2,107 USD
Market Cap
0.93T JPY 5.98B USD
Number of Trades
2,728
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
2,781
1-Year High Feb 10, 2025
20,343
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 81,200 287,000 3.53
Nov 28, 2025 140,100 312,600 2.23
Nov 21, 2025 440,700 460,400 1.04
Nov 14, 2025 82,700 546,900 6.61
Nov 7, 2025 84,900 660,500 7.78
Company Profile
Meiji Holdings Co., Ltd. was formed through the integration of Meiji Seika and Meiji Dairies. It is the largest company in the confectionery and dairy industries. The company's pharmaceutical business is experiencing rapid growth, and it is expanding globally.
Sector
Foods
Meiji Holdings Co., Ltd. operates in two business segments: Food and Pharmaceuticals. In the Food segment, the company handles a wide range of products including dairy products, confectioneries, nutritional foods, and animal feed, conducting business through numerous subsidiaries and affiliated companies both domestically and internationally. The Pharmaceutical segment focuses primarily on prescription drugs and veterinary medicines, manufacturing and selling these products through domestic and overseas subsidiaries. As a pure holding company, Meiji Holdings is responsible for formulating group-wide strategies and managing operations. Meiji Co., Ltd. is positioned as the core company in the food business, while Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd. are the core companies in the pharmaceutical business. The company is also focusing on global expansion, with numerous overseas subsidiaries, particularly in Asia.